Pursuing innovation as diverse as lung cancer itself

There is no single lung cancer experience. Its complexity stretches across subtypes, stages, treatment settings and patient needs. Our commitment reflects that complexity. We are advancing multiple investigational approaches across the diverse spectrum of lung cancer, informed by the needs and experiences of patients and the broader lung cancer community.

Clinical trials for lung cancer treatment

Therapeutic approaches and modalities

Investigational medicines

Lung cancer is not one disease

Lung cancer can look very different from one person to the next - shaped by factors such as subtype, stage, biomarkers, treatment history and individual patient needs. Understanding those differences is essential to advancing more tailored approaches across the disease.

*The overview of categories is not exhaustive and is intended to illustrate BioNTech’s current focus within lung cancer.

Types

Non-small cell and small cell lung cancer, non-squamous and squamous

Stages

Early stage, advanced/locally advanced, unresectable disease, and metastatic

Biomarkers

Molecular characteristics such as PD-L1 expression and genomic alterations

Treatment status

Untreated, previously treated, progressed or relapsed

Patient factors

Treatment history, age, overall health and comorbidities

Our approach and therapeutic modalities

Next-generation immunomodulators

We are investigating next-generation immunomodulators designed to address tumor-specific immune suppression and other biological mechanisms that may limit the effectiveness of current immuno-oncology therapies.

mRNA-based cancer immunotherapies

We are developing mRNA-based cancer immunotherapies designed to help the immune system recognize cancer targets that are unique to an individual patient or shared across a tumor type. In lung cancer, these investigational approaches are being explored as part of a broader portfolio designed to address the biological complexity of the disease.

Antibody-drug conjugates

Antibody-drug conjugates (ADCs) are a class of precision cancer therapies that combine tumor-specific selectivity of antibodies, with the cell-killing features of an anti-cancer chemotherapy.

Our ambition in lung cancer care

Every innovation that we pursue starts with the needs of patients. The future of lung cancer treatment will require more than a single approach. We are committed to building across the complexity of the disease, advancing complementary therapeutic strategies, including combination approaches, designed to address distinct biological challenges with patients at the center.

Claudia-Nanette Gann, M.D. – Vice President Global Medical Affairs

Our pipeline of lung cancer therapies

Our work in lung cancer care brings together three complementary therapeutic modalities: next-generation immunomodulators, antibody-drug conjugates and mRNA-based cancer immunotherapies. We believe each may offer a precise mechanism for targeting cancer cells while creating opportunities to explore synergistic combinations, including regimens combining two novel therapies. We are committed to delivering differentiated therapeutic approaches for patients across the lung cancer continuum - from early to late stages of the disease. 

 Explore our lung cancer pipeline to learn more about the programs and combinations we are advancing, including their targets and development status.

Learn more

Our clinical trials in lung cancer

Clinical trials are essential to translating scientific innovation into potential new treatment options for people with lung cancer. Discover BioNTech-sponsored clinical trials and studies currently underway or enrolling participants across lung cancer.

Find a BioNTech clinical trial

Explore more

Platforms

Learn how BioNTech’s technology platforms support the development of mRNA-based cancer immunotherapies, next-generation immunomodulators and targeted therapies.

Learn more